RE:RE:Memoriesriverrrow wrote: Since recruitment and treatment of more patients for our clinical trial is on hold until this coronavirus problem has been put to rest I suppose anything related to solving the coronavirus issue is relevant to TLT. GLTA.
BOTTOM LINE we have 12 treated Cohort A P1-P6 Cohort B P7-P12 with results in the WINGS
VALUATION: at a PHASE 1 level should be 160m cap at a minimum just for Bladder C..
Our other 2 indications target GBM and the largest market in LUNG cancer.... which can cause big time speculation
Biotechs that have technology and find JV like I suggested just on an NR of a partnership go up massively.
None of what Ive said has anything to do with Corona-Excuses for TLT.
We are very fortunate that the 2nd treatments are being permitted and speaks even further to the very expertise and 'outpatient' potential of this treatment modality. Afterall it's basically a modified cystoscope with laser light + dosimeter.
Im beyond sick of this sandbagging